$RGPX
REGENEREX PHARMA, INC.

2022 Q4 Form 10-Q Financial Statement

#000147237522000113 Filed on November 07, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2022 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $29.10K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.071K
YoY Change 115.49%
% of Gross Profit
Operating Expenses $29.10K $21.50K $17.29K
YoY Change -53.04% 2.05% 47.89%
Operating Profit -$29.10K -$21.50K -$17.29K
YoY Change -53.04% 2.05% 47.89%
Interest Expense $17.24K $16.61K $15.52K
YoY Change 18.51% -1.38% 21.79%
% of Operating Profit
Other Income/Expense, Net -$20.30K $3.068K -$5.919K
YoY Change 23.49% -130.02% -65.16%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$49.40K -$18.44K -$23.20K
YoY Change -37.81% -45.38% -31.66%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 277.1M shares 277.1M shares 277.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 Q3 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $1.203K $629.00 $1.672K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $2.500K $2.500K $2.500K
Receivables
Other Receivables
Total Short-Term Assets $3.703K $3.129K $4.172K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $6.226K $5.632K $6.355K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.703K $3.129K $4.172K
Total Long-Term Assets $6.226K $5.632K $6.355K
Total Assets $9.929K $8.761K $10.53K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $66.13K $66.19K $57.49K
YoY Change
Accrued Expenses $118.3K $104.3K $88.83K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $874.9K $780.4K $746.9K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $874.9K $780.4K $746.9K
Total Long-Term Liabilities
Total Liabilities $1.087M $1.036M $1.019M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$2.026M -$1.976M -$1.958M
YoY Change
Common Stock $277.1K $277.1K $277.1K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.077M -$1.027M -$1.009M
YoY Change
Total Liabilities & Shareholders Equity $9.929K $8.761K $10.53K
YoY Change

Cashflow Statement

Concept 2022 Q4 2022 Q3 2022 Q2
OPERATING ACTIVITIES
Net Income -$49.40K -$18.44K -$23.20K
YoY Change -37.81% -45.38% -31.66%
Depreciation, Depletion And Amortization $1.071K
YoY Change 115.49%
Cash From Operating Activities -$35.07K
YoY Change 55.91%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $34.10K
YoY Change 58.27%
NET CHANGE
Cash From Operating Activities -$35.07K
Cash From Investing Activities
Cash From Financing Activities $34.10K
Net Change In Cash -$968.00
YoY Change 2.11%
FREE CASH FLOW
Cash From Operating Activities -$35.07K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89108
dei City Area Code
CityAreaCode
(702)
dei Entity Central Index Key
EntityCentralIndexKey
0001357878
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Interest Paid
InterestPaid
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53230
dei Entity Registrant Name
EntityRegistrantName
REGENEREX PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0479983
dei Entity Address Address Line1
EntityAddressAddressLine1
5348 Vegas Drive #177
dei Local Phone Number
LocalPhoneNumber
273-3772
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
277112660 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
629 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2640 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2500 usd
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5256 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
3129 usd
CY2022Q1 us-gaap Assets Current
AssetsCurrent
7896 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
24968 usd
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
23174 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5632 usd
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7426 usd
CY2022Q3 us-gaap Assets
Assets
8761 usd
CY2022Q1 us-gaap Assets
Assets
15322 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
66191 usd
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
63027 usd
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
139287 usd
CY2022Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
131687 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
221192 usd
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
221192 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
104257 usd
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91667 usd
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
249427 usd
CY2022Q1 us-gaap Notes Payable Current
NotesPayableCurrent
152880 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
780354 usd
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
660453 usd
CY2022Q3 us-gaap Notes Payable
NotesPayable
255664 usd
CY2022Q1 us-gaap Notes Payable
NotesPayable
340486 usd
CY2022Q3 us-gaap Liabilities
Liabilities
1036018 usd
CY2022Q1 us-gaap Liabilities
Liabilities
1000939 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
277112660 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
277112660 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
277112660 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
277112660 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
277113 usd
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
277113 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
671963 usd
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
671963 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1976333 usd
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1934693 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1027257 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-985617 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8761 usd
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15322 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21504 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21073 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38789 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32761 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
21504 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
21073 usd
us-gaap Operating Expenses
OperatingExpenses
38789 usd
us-gaap Operating Expenses
OperatingExpenses
32761 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21504 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21073 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-38789 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-32761 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
16607 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
16840 usd
us-gaap Interest Expense
InterestExpense
32125 usd
us-gaap Interest Expense
InterestExpense
29582 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
19675 usd
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6619 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
29274 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2372 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3068 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10221 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2851 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27210 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-18436 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-31294 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-41640 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-59971 usd
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-2462 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-7737 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18436 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-33756 usd
us-gaap Net Income Loss
NetIncomeLoss
-41640 usd
us-gaap Net Income Loss
NetIncomeLoss
-67708 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.00
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.00
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.00
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.00
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
277112660 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127112660 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
277112660 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127112660 shares
us-gaap Net Income Loss
NetIncomeLoss
-41640 usd
us-gaap Net Income Loss
NetIncomeLoss
-67708 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-7737 usd
us-gaap Depreciation
Depreciation
1794 usd
us-gaap Depreciation
Depreciation
1314 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
29274 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2372 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2756 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1623 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
21852 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
24932 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-44512 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-37720 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-7737 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44512 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45457 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5600 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
7600 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
34901 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
46700 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42501 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46700 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2011 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4357 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2640 usd
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6902 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
629 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2545 usd
reg1357878 Accrued Interest Converted Into Note Payable To Shareholder
AccruedInterestConvertedIntoNotePayableToShareholder
4015 usd
reg1357878 Accrued Interest Converted Into Note Payable To Shareholder
AccruedInterestConvertedIntoNotePayableToShareholder
13451 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-835026 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-33952 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-868978 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-868978 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-33756 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-902734 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-985617 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23204 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1008821 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1008821 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18436 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1027257 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 1 – NATURE OF OPERATIONS</b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><b> </b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.  The Company’s business was to develop and market proprietary skincare products that was to be sold online. The majority of manufacturing, distribution, marketing, and sales operations was outsourced.  The Company’s attempt over the past four years to build a business that marketed skincare products online has not come to fruition, so management decided to change the business focus and look for other opportunities.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15<sup>th</sup> of the following month, for a period of 60 months.  The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  These unique products strategically position the Company to enter the wound treatment market in the U.S.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Management has decided to focus on this new business development.  The financial results for periods prior to the abandonment of the previous business line have been reflected in the accompanying statement of operations as discontinued operations as this change represented a strategic shift in our business that had a major effect on our operations and financial results.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Risks and Uncertainties </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position and cash flows.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has a lack of revenue history and has had a limited history of operations.  No revenue has historically been derived from the assets purchased.  Regenerex can give no assurance of success or profitability to the Company’s investors.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The wound care healing space is well suited for Home Care service providers that are funded by the US Government. The majority of manufacturing and distribution will be outsourced. However, strategic planning and development will be performed internally by the Company.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-18
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
10000000 usd
CY2022Q3 reg1357878 Current Liabilities In Excess Of Current Assets
CurrentLiabilitiesInExcessOfCurrentAssets
1027257 usd
us-gaap Property Plant And Equipment Preproduction Design And Development Costs
PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts
<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Website</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and six months ended September 30, 2022 and 2021 was $723 and $816 and $1,794 and $1,314, respectively.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p>
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
723 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
816 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1794 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1314 usd
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
139287 usd
CY2022Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
131687 usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
6732 usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
6568 usd
us-gaap Debt Instrument Maturity Date Range Start1
DebtInstrumentMaturityDateRangeStart1
2022-10-23
us-gaap Debt Instrument Maturity Date Range End1
DebtInstrumentMaturityDateRangeEnd1
2024-08-24
CY2022Q3 us-gaap Accounts Payable Interest Bearing Current And Noncurrent
AccountsPayableInterestBearingCurrentAndNoncurrent
102858 usd
CY2022Q1 us-gaap Accounts Payable Interest Bearing Current And Noncurrent
AccountsPayableInterestBearingCurrentAndNoncurrent
74748 usd
CY2021Q4 us-gaap Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
150000000 shares
CY2021Q4 us-gaap Business Combination Contingent Consideration Arrangements Description
BusinessCombinationContingentConsiderationArrangementsDescription
up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months

Files In Submission

Name View Source Status
0001472375-22-000113-index-headers.html Edgar Link pending
0001472375-22-000113-index.html Edgar Link pending
0001472375-22-000113.txt Edgar Link pending
0001472375-22-000113-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ixform10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ixform10q_htm.xml Edgar Link completed
R8.htm Edgar Link pending
R9.htm Edgar Link pending
reg1357878-20220930.xsd Edgar Link pending
regenerexlogo.gif Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
reg1357878-20220930_cal.xml Edgar Link unprocessable
reg1357878-20220930_def.xml Edgar Link unprocessable
reg1357878-20220930_lab.xml Edgar Link unprocessable
reg1357878-20220930_pre.xml Edgar Link unprocessable